-Advertisement-
-Advertisement-
IOL Insertion/Toric IOLs

FDA approves next-generation presbyopia-correcting IOLs

Posted on May 11, 2021
FDA grants breakthrough therapy designation for ALK-001 for Stargardt Disease

The U.S. Food and Drug Administration has approved Tecnis Synergy and Tecnis Synergy Toric II IOLs (Johnson & Johnson Vision), according to a press release.

According to a company-sponsored study, 9 out of 10 patients who received the IOL lenses did not need glasses after surgery.

“The Tecnis Synergy IOL combines the best of extended depth of focus and multifocal technologies – to deliver the widest range of continuous vision with the best near vision among leading [presbyopia-correcting intraocular lens], without the visual gaps caused by existing trifocal technology,” said Rajesh Rajpal, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision in the press release. “Additionally, we’ll offer Tecnis Synergy IOL on our new Toric II platform, when it launches later this year, to give surgeons the ability to address astigmatism at the time of surgery.”

Read the full press release here.

-Advertisement-
Related Articles
New IOL technology in 2020
Nov 15, 2020
Sutureless Flanged IOL Fixation May be Efficient Alternative to Conventional Treatment for IOL Dislocation
Apr 08, 2020
Visual Performance Evaluated in Contralateral, Bilateral Implantation of IC-8 IOL
Jan 28, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-